Abstract
AbstractDrug repurposing, the process of finding new uses for existing drugs, has gained considerable attention due to its potential to reduce the time and costs associated with drug development. Personalized drug repurposing, in which drugs are selected based on the characteristics of individual patients, is an emerging approach that holds promise for improving clinical outcomes. In this context, exploring disease-drug pairs in already conducted clinical trials can provide valuable insights to identify promising patient populations for further study that may lead to personalized drug repositioning. Our analysis aims to shed a light into clinical outcomes by selecting the most appropriate repurposed drug based on clinical trials patient groups’ characteristics, such as age and gender. It also gives information about the state of the clinical trials studying these disease-drug pairs, gathering information about the study type, phase and statistical method used to calculate the p-value of the chosen outcome measurement, among others. Overall, this study highlights the importance of using existing knowledge as an initial framework to facilitate further research, particularly in providing patient-specific information. Furthermore, it underlines the importance of building on previous research to facilitate a comprehensive understanding of the research topic, which can eventually improve patient outcomes.
Publisher
Cold Spring Harbor Laboratory
Reference14 articles.
1. Drug repositioning for personalized medicine
2. A data-driven methodology towards evaluating the potential of drug repurposing hypotheses
3. Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis
4. Personalized medicine: motivation, challenges, and progress
5. M. T. Md , “A Phase II, Randomized, Double-blinded, Placebocontrolled Trial of Liraglutide in Parkinson’s Disease,” clinicaltrials.gov, Clinical trial registration NCT02953665 , Oct. 2022. Accessed: Jan. 30, 2023. [Online]. Available: https://clinicaltrials.gov/ct2/show/NCT02953665